Cypress Reaches Settlement With Glaxo Group Limited Relating to Ranitidine Oral Syrup Products
Posted on: Friday, 25 January 2008, 09:00 CST
Cypress Pharmaceutical, Inc. today announced that it has reached a settlement with Glaxo Group Limited (Glaxo), part of the GlaxoSmithKline group of companies, resolving all disputes between the companies related to Cypress' generic ranitidine oral solution products and Glaxo's Zantac® syrup.
Under the terms of the settlement, Glaxo has agreed not to assert its patent against Cypress' new alcohol-free formulation of its generic ranitidine oral syrup. Cypress expects to launch the product immediately upon receiving FDA approval. As a result of the settlement, the parties filed a stipulation to dismiss their patent litigation pending in the U.S. District Court for the Southern District of New York.
Cypress Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development and marketing of prescription products to pharmaceutical wholesalers, chain drug stores, distributors, and other retail merchandisers in the United States. For more information about Cypress, visit www.cypressrx.com.
Source: Business Wire
Related Articles
- Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
- Cypress Pharmaceutical, Inc. Receives FDA Approval of Cetirizine Hydrochloride Oral Solution
- Cypress Settles Ranitidine Oral Syrup Dispute With Glaxo
- Company Profile for Cypress Pharmaceutical, Inc.
- Cypress Pharma and Standard Chemical Sign Marketing Agreement
- Cypress Pharmaceutical, Inc. And Standard Chem. & Pharm. Co., Ltd. Enter into Development and Marketing Agreement
- Jazz Pharmaceuticals Announces Settlement of Government Investigation
- FAST 40: Generic Drug Niche Grows for Cypress Pharmaceutical
- Glaxo to Settle Drug Price Fraud Case
 |
 |
User Comments (0)
RSS Feeds